1st May 2014 05:33
LONDON (Alliance News) - GlaxoSmithKline PLC Wednesday said FDA has approved Incruse Ellipta, or umeclidinium, as treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.
Umeclidinium is GSK's first once-daily anticholinergic, a type of bronchodilator also known as a long-acting muscarinic antagonist.
The launch activities in the US is expected to commence during the fourth quarter.
Copyright RTT News/dpa-AFX
Related Shares:
Glaxosmithkline